1. Promotor methylation status of MAPK4 is a novel epigenetic biomarker for prognosis of recurrence in patients with thymic epithelial tumors
   Wei Guan et al, 2022, Thoracic Cancer CrossRef
2. Insights into the leveraging of GABAergic signaling in cancer therapy
   Tian‐Jiao Li et al, 2023, Cancer Medicine CrossRef
3. GABAergic signaling beyond synapses: an emerging target for cancer therapy
   De Huang et al, 2023, Trends in Cell Biology CrossRef
4. GABAergic signaling as a potential therapeutic target in cancers
   Yihui Yang et al, 2023, Biomedicine & Pharmacotherapy CrossRef
5. miR-4284 Functions as a Tumor Suppressor in Renal Cell Carcinoma Cells by Targeting Glutamate Decarboxylase 1
   Sujin Choi et al, 2023, Cancers CrossRef
6. Thymic Epithelial Neoplasms: Focusing on the Epigenetic Alterations
   Iason Psilopatis et al, 2022, International Journal of Molecular Sciences CrossRef
7. Epigenetics of Thymic Epithelial Tumors
   Vanessa Nicolì et al, 2023, Cancers CrossRef
8. The 2021 WHO Classification of Tumors of the Thymus and Mediastinum: What Is New in Thymic Epithelial, Germ Cell, and Mesenchymal Tumors?
   Alexander Marx et al, 2022, Journal of Thoracic Oncology CrossRef
9. Thymic Carcinomas—A Concise Multidisciplinary Update on Recent Developments From the Thymic Carcinoma Working Group of the International Thymic Malignancy Interest Group
   Anja C. Roden et al, 2022, Journal of Thoracic Oncology CrossRef
10. A GAD1 inhibitor suppresses osteosarcoma growth through the Wnt/β-catenin signaling pathway
    Changchun Jian et al, 2024, Heliyon CrossRef
11. Aberrant DNA Methylation of NPTX2 as an Indicator of Malignant Behavior in Thymic Epithelial Tumors
    Kazuya Kondo et al, 2024, Cancers CrossRef